Ibrutinib

Generic Name
Ibrutinib
Brand Names
Imbruvica
Drug Type
Small Molecule
Chemical Formula
C25H24N6O2
CAS Number
936563-96-1
Unique Ingredient Identifier
1X70OSD4VX
Background

Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell ...

Indication

Ibrutinib is indicated for the treatment of the following conditions.

Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Waldenström's macroglobulinemia

Chronic graft-versus-host disease (cGVHD)

Mantle cell lymphoma (MCL)

Marginal zone lymphoma (MZL)

Associated Conditions
Chronic Graft-Versus-Host Disease, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma (MZL), Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Steroid-dependent chronic graft-versus-host disease, Waldenström's Macroglobulinemia (WM), Steroid refractory Chronic graft versus host disease
Associated Therapies
-
Clinical Trials
Related News

A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

First Posted Date
2021-05-06
Last Posted Date
2024-12-06
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
45
Registration Number
NCT04876092
Locations
🇫🇷

Institut Paoli Calmettes, Marseille, France

🇫🇷

Hopital St Louis, Paris, France

🇩🇰

Rigshospitalet, Copenhagen, Denmark

and more 7 locations

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

First Posted Date
2021-04-12
Last Posted Date
2024-12-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
92
Registration Number
NCT04840602
Locations
🇺🇸

Springfield Memorial Hospital, Springfield, Illinois, United States

🇺🇸

Cancer Hematology Centers - Flint, Flint, Michigan, United States

🇺🇸

Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States

and more 101 locations

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

First Posted Date
2021-03-04
Last Posted Date
2024-10-24
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
50
Registration Number
NCT04781855
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)

First Posted Date
2021-02-25
Last Posted Date
2021-02-25
Lead Sponsor
Jeanette Lundin
Target Recruit Count
50
Registration Number
NCT04771507
Locations
🇳🇴

St Olavs Hospital, Trondheim, Norway

🇸🇪

Gävle Hospital, Gävle, Gävleborg, Sweden

🇸🇪

Skåne University Hospital, Lund, Skåne, Sweden

and more 6 locations

Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)

First Posted Date
2021-02-17
Last Posted Date
2023-10-04
Lead Sponsor
Paolo Ghia
Target Recruit Count
55
Registration Number
NCT04758975
Locations
🇮🇹

IRCCS Ospedale San Raffaele, Milano, MI, Italy

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

First Posted Date
2021-02-05
Last Posted Date
2024-12-12
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
55
Registration Number
NCT04739813
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL

First Posted Date
2020-12-28
Last Posted Date
2023-01-17
Lead Sponsor
Inhye Ahn
Registration Number
NCT04685915

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

First Posted Date
2020-12-11
Last Posted Date
2022-08-03
Lead Sponsor
Academic and Community Cancer Research United
Registration Number
NCT04665115
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

First Posted Date
2020-12-10
Last Posted Date
2024-05-13
Lead Sponsor
Loxo Oncology, Inc.
Target Recruit Count
500
Registration Number
NCT04662255
Locations
🇺🇸

Mercy Health-Paducah Medical Oncology and Hematology, Paducah, Kentucky, United States

🇺🇸

Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States

🇺🇸

Seattle Cancer Care Alliance, Seattle, Washington, United States

and more 220 locations

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

First Posted Date
2020-10-29
Last Posted Date
2023-01-25
Lead Sponsor
Karyopharm Therapeutics Inc
Target Recruit Count
350
Registration Number
NCT04607772
Locations
🇺🇸

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

🇺🇸

US Oncology - Oncology Associates of Oregon, Eugene, Oregon, United States

🇺🇸

University of Texas Southwestern, Dallas, Texas, United States

and more 15 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy